Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Triamcinolone acetonide + dimethicone** is a topical combination drug indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses[1][5][7]. Triamcinolone acetonide is a synthetic fluorinated corticosteroid that reduces skin inflammation, itching, and redness by inhibiting phospholipase A2, thereby reducing synthesis of pro-inflammatory mediators[6][8]. Dimethicone is an emollient and skin protectant, used to moisturize, soothe, and protect the skin barrier. This combination product is applied as a cream or ointment to treat conditions including eczema, psoriasis, dermatitis, and other inflammatory skin disorders[7][8]. Triamcinolone acetonide acts as an agonist at the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects[6]. Dimethicone forms a protective barrier over the skin, reducing moisture loss and providing symptomatic relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triamcinolone acetonide + dimethicone.